Comparison of Abiraterone Acetate Versus Ketoconazolein Patients with Metastatic Castration Resistant Prostate Cancer Refractory to Docetaxel

BACKGROUND: Abiraterone, a potent CYP 17 inhibitor, is standard treatment in docetaxel refractory, metastatic castrate resistant prostate cancer (mCRPC). However, in countries where abiraterone has not been approved yet, or for patients who cannot afford it, ketoconazole is used as an alternative CY...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate
Main Authors: Peer, Avivit, Gottfried, Maya, Sinibaldi, Victoria, Carducci, Michael A., Eisenberger, Mario A., Sella, Avishay, Leibowitz-Amit, Raya, Berger, Raanan, Keizman, Daniel
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4696030/
https://ncbi.nlm.nih.gov/pubmed/24338986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados